Historically, cancer treatments have been very invasive and detrimental to the body as a whole. However, there are numerous new techniques available for those with cancer that are not as invasive and detrimental to the body as a whole. These treatments range from the severely alternative to the more traditional. Kinase Inhibitors are one of these treatments known to mitigate the spread of cancerous cells. In the past, the treatment of choice was to remove the cancer and as much of the surrounding normal tissue as possible. Therefore most of the surgical procedures used were considered to be radical in nature. In the mid-1950s even though the radical procedures were technically sophisticated, the mortality rates associated with certain cancer sites were not improving. Many cancers that were thought to be local disease processes were found to be systemic diseases with metastatic lesions located in anatomic sites other than the site of the primary disease. On analysis of these findings, it became obvious that surgery alone regardless of the extent of the procedure was not an effective treatment for every type of cancer.
There have been many cancer therapeutics approved over the last 50+ years for a wide range of cancer indications. The largest numbers of treatments approved are for breast cancer, leukemia, lung cancer, and lymphoma.
The market for one type of these treatments, kinase inhibitors is heating up. Although the market is becoming more established and several billion dollar drugs have emerged this segment has enormous room for growth.
Several factors continue to influence the double-digit growth this market has experienced, including the continued success of targeted therapy in cancer treatment, rising incidence of cancer, and increased cost for newly approved therapies in the advanced treatment area.
Our new Kalorama Information market research report – The Next Wave in Cancer Treatment--Kinase Inhibitors - is focused on a growing area of cancer treatment, kinase inhibitors. Several cancers are being treated with these newer therapies, which provide a focus of cancer profiled in this report, including: